ORIC Pharmaceuticals GAAP EPS of -$0.52 beats by $0.02 Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-K Oric Pharmaceuticals, For: Dec 31 Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in…
Oric Pharmaceuticals upgraded to outperform from perform at Oppenheimer Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…
ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting ORIC-944 preclinical poster presentation to highlight comprehensive biomarker strategy for ongoing Phase 1 trial in metastatic prostate cancer...…
ORIC Pharmaceuticals to Participate in the Oppenheimer 33rd Annual Healthcare Conference SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC),…
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC),…
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC),…
Form 8-K Oric Pharmaceuticals, For: Jan 09 Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
ORIC Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC),…